Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT06158802
Other study ID # APHP210417
Secondary ID 2021-A02421-40
Status Recruiting
Phase
First received
Last updated
Start date January 23, 2024
Est. completion date July 2024

Study information

Verified date November 2023
Source Assistance Publique - Hôpitaux de Paris
Contact Sabrina DA COSTA, MD
Phone 1 44 49 48 04
Email sabrina.dacosta@aphp.fr
Is FDA regulated No
Health authority
Study type Observational

Clinical Trial Summary

The main objective of the study is to determine the vaccination coverage rate for human papillomavirus in adolescents aged 11 to 20 with chronic disease and treated at the Necker-Enfants Malades Hospital, compared to a population witnessed adolescent girls aged 11 to 20 years without chronic disease.


Description:

Girls and young women with chronic condition are at higher risk for infections that can be prevented by vaccination. Human papillomavirus infection is very common, one of the three most common in the general population. A vaccine exists to significantly prevent this infection and its complications. In France, it is advisable to vaccinate girls and boys from the age of 9 years and as soon as possible in the case of acquired immunodeficiency since these patients are more likely to be suffering from cancer induced by the human papillomavirus. In France, the overall rate of vaccination coverage for girls is 21%, which is significantly lower than in several other industrialized countries. The vaccination coverage rate for human papillomavirus in patients with chronic diseases may be even lower. The main objective of the study is to determine the vaccination coverage rate for human papillomavirus in adolescents aged 11 to 20 with chronic condition and treated at the Necker-Enfants Malades Hospital, compared to a population witnessed adolescent girls aged 11 to 20 years without chronic disease.


Recruitment information / eligibility

Status Recruiting
Enrollment 448
Est. completion date July 2024
Est. primary completion date July 2024
Accepts healthy volunteers No
Gender Female
Age group 11 Years to 20 Years
Eligibility Inclusion Criteria: - Information and non-opposition of major patients and holders of parental authority of minor patients and minor patients - Girls and young women aged 11 to 20 - To be followed at the Necker-Enfants Malades Hospital ("chronic condition" group) - To be followed at the Specialized Medical Center for Children and Adolescents ("control" group) - Have a chronic condition ("chronic condition" group) : - Diabetes type 1 - Metabolic diseases - Patients followed in immuno-hematology - Cystic Fibrosis - Sickle - Kidney transplant - Heart Disease - Inflammatory bowel diseases - Rare anorectal and pelvic anomalies - Live in France - Comprehension of the French language (oral and written) Exclusion Criteria: - Have a contraindication to the HPV vaccine - Gardasil 9 (Vidal Hoptimal, 2018) - Have a contraindication to the HPV vaccine - Gardasil (Vidal Hopitmal, 2018) - Have a contraindication to HPV vaccine - Cervarix (Vidal Hoptimal, 2018)

Study Design


Related Conditions & MeSH terms


Intervention

Other:
Questionnaire
Questionnaire on human papillomavirus vaccine status of girls and young women and modalities of the vaccination or reason of the non-vaccination. The questionnaire is completed by the patient.

Locations

Country Name City State
France Centre Médical Spécialisé de l'Enfant et de l'Adolescent (CMSEA) Paris
France Hôpital Necker-Enfants Malades Paris

Sponsors (1)

Lead Sponsor Collaborator
Assistance Publique - Hôpitaux de Paris

Country where clinical trial is conducted

France, 

References & Publications (3)

Gras-Le Guen C, Legrand A, Caquard M, Micaelli X, Picherot G, Lacroix S, Volteau C, Launay E. Chronically ill adolescents are also incompletely vaccinated: A cross-sectional study in France. Vaccine. 2017 Aug 24;35(36):4707-4712. doi: 10.1016/j.vaccine.2017.07.042. Epub 2017 Jul 29. — View Citation

Hoffman L, Okcu MF, Dreyer ZE, Suzawa H, Bryant R, Middleman AB. Human papillomavirus vaccination in female pediatric cancer survivors. J Pediatr Adolesc Gynecol. 2012 Oct;25(5):305-7. doi: 10.1016/j.jpag.2012.05.004. Epub 2012 Jul 24. — View Citation

Hofstetter AM, Camargo S, Natarajan K, Rosenthal SL, Stockwell MS. Vaccination Coverage of Adolescents With Chronic Medical Conditions. Am J Prev Med. 2017 Nov;53(5):680-688. doi: 10.1016/j.amepre.2017.07.017. Epub 2017 Sep 18. — View Citation

Outcome

Type Measure Description Time frame Safety issue
Primary Immunization coverage rate for human papillomavirus vaccine Percentage of patients with or without a chronic illness who have received HPV vaccination (complete vaccination schedule). Day 1
Secondary Intention of vaccination by human papillomavirus vaccine by the usual health professionals Percentage of patients with or without a chronic illness who have been offered HPV vaccination. Day 1
Secondary Category of health professionals offering vaccination by human papillomavirus vaccine Patients with or without a chronic illness to whom vaccination has been offered/prescribed :
Percentage of vaccination offered/prescribed by the general practitioner
Vaccination percentage proposed/prescribed by the pediatrician,
Vaccination percentage proposed/prescribed by the gynecologist,
Percentage of vaccination proposed/prescribed by the specialist doctor,
Percentage of vaccination offered/prescribed by another healthcare professional.
Day 1
Secondary Reasons for non-vaccination by human papillomavirus vaccine Patients suffering from a chronic illness or not and not vaccinated:
Percentage of patients not vaccinated due to fear/apprehension,
Percentage of patients not vaccinated because they did not know this vaccine,
Percentage of patients not vaccinated because they are against vaccination,
Percentage of patients not vaccinated due to lack of time.
Day 1
Secondary Description of parameters that may impact vaccination coverage for human papillomavirus vaccine Description of patients with or without a chronic illness and vaccinated or not against HPV
Average age of patients at the time of inclusion,
Socio-professional category of parents (father's and mother's profession),
Average age at menarche,
Assessment of risk behaviors (percentage of patients who smoke, percentage of patients who consume alcohol),
Percentage of patients who have started their sexual life,
Average age at first sexual intercourse,
Percentage of patients followed by a pediatrician,
Percentage of patients followed by a general practitioner,
Percentage of patients followed by a gynecologist.
Day 1